The development of ectolysins against Gram negative bacteria is a challenge due to the presence of an impermeable outer membrane that prevents access to the Gram negative peptidoglycan layer of the cell wall.
GangaGen has successfully overcome this challenge to discover and engineer lysins with broad spectrum activity against human pathogens such as Acinetobacter baumannii and Pseudomonas aeruginosa.
GangaGen's Gram negative ectolysins are potent in diverse in vitro studies including demonstrated activity in relevant biological fluids and in vivo studies. GangaGen aims to develop these ectolysins as an intravenous therapeutic for human applications.